Skip to main content
OpenTrials
Completed

NCT Number: NCT03487887

Secondary Care - Continuous Glucose Monitoring

Introduction and objective: The current state of glucose monitoring includes the use of A1C, self-monitoring of blood glucose (SMBG), and continuous glucose monitoring (CGM). CGM technology has got the potential to revolutionize diabetes care in the near future striving to optimal diabetes management and tight glucose control. Until very recently, this determination could only be achieved by the attainment of multiple capillary blood glucose determinations each day and/or measuring hemoglobin A1C. Those methods are not accurate in cases of unrecognized hypoglycemia, unrecognized nighttime events or in cases of large swings in blood glucose. Our aim is to analyze the benefit of tracking patterns of glucose values by using professional CGM technology used for "blinded" collection of glucose data retrospectively in patients with T2DM in secondary care- diabetologist clinic.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 day–8 day

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Centre Zagreb

Zagreb, 10 000, Croatia

About this study

STUDY DESIGN: An observational, multicenter, cross-sectional study. A total of 20 diabetologist from four Croatian regions will recruit up to ten subjects of both sexes from May 2018 till the end of May 2019, diagnosed with type 2 diabetes mellitus at least one year prior to study entry, aged ≥40 years, with only basal insulin in therapy and with clinical suspicion of hypoglycemia or with disproportion in actual glycaemia and hemoglobin A1c findings. Sociodemographic, laboratory (HbA1c, fasting and postprandial glucose, total cholesterol, and high density cholesterol, and low density cholesterol, triglyceride and serum creatinine) and habits data will be collected.

SETTING: Totally 100 of patients will be included. At diabetologist office each patient wear the device (iPro™2 Medtronic) subcutaneously for up to 7-days and return it to the office for download. Patients only see the CGM data after it's been analyzed by the healthcare professional. A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist who are not familiar to the method will have a short education. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • T2DM diagnosed at least one year prior to study entry
  • Only basal insulin in therapy
  • Patients' ability to understand and answer the questionnaire by themselves
  • Signed informed consent

Exclusion criteria

  • Known coagulopathy
  • Oral anticoagulants in therapy
  • Skin disease that enables continuous glucose monitor device application
  • Febrile illness
  • Patient's inability to physically visit a general practitioners office
  • Patient's inability to answer the questionnaire by themselves

Treatment and study plan

continuous glucose monitoring (CGM) iPro™2 Medtronic

Device

A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.

Primary outcomes

  1. Glycemic variability

    Time frame: 7 days

    Glycemic variability measured by continuous glucose monitor devicein individuals with type 2 diabetes mellitus in secondary care

Secondary outcomes

  1. Hypogliaemia

    Time frame: 7 days

    Hypogliaemia measured by continuous glucose monitor device in individuals with type 2 diabetes mellitus in secondary care

Sponsors and collaborators

Lead sponsor

Croatian Society for Endocrinology and Diabology

Other

Collaborators

  • Takeda

Registry information

Official study title

Continuous Glucose Monitoring in Patients With Diabetes Mellitus Type 2 in Secondary Care

Acronym: SC-COSMO

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Apr 4, 2018
Registry last updated
Sep 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.